Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with ...

Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204's Innovative Delivery ...

The published data showed that the combination of avutometinib plus defactinib demonstrated a confirmed overall response rate of 31% in all patients with recurrent low-grade serous ovarian cancer ...

Verastem shows strong late-stage pipeline progress, financial discipline, and a diverse portfolio that support long-term growth. Learn why VSTM stock is a buy.

Revolution Medicines Inc. (NASDAQ:RVMD) is one of the most promising stocks according to Wall Street analysts. On June 23, Revolution Medicines announced that the US FDA granted Breakthrough Therapy ...

These findings highlight the dual roles of antioxidants in cancer. Their impact depends on cancer type, stage, and genetic ...

Daraxonrasib gains FDA breakthrough therapy status for treating metastatic pancreatic cancer with KRAS G12X mutations, ...

After 77 years, one of India’s most respected conglomerates got it’s first non family CEO In 2020, as the world grappled with the uncertainty of the COVID-19 crisis, Anish Shah stepped into the role ...

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors Phase 1 dose-escalation study to ...

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene - a gene that can cause cancer - that may play an important role in colon cancer. Researchers also showed how ...

She’s at her pre-K promotion ceremony—but her joy isn’t for herself. It’s for her classmate, who is neurodivergent and ...